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NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS
INCREASES RISK OF HOSPITALIZATIONS FOR STROKE BY
NEARLY 20%
Breekveldt-Postma NS1, Siiskonen SJ1, Penning-van Beest FJA1,
Erkens JA1,Vincze G2, Falvey H2, Herings RMC1
1PHARMO Institute, Utrecht,The Netherlands, 2Novartis Pharma AG,
Basel, Switzerland
OBJECTIVES: Low persistence with antihypertensive drug treat-
ment (AHT) is expected to limit patient’s beneﬁts in terms of a
reduction of cardiovascular and cerebrovascular disease. This
study investigated the relationship between persistence with anti-
hypertensive drugs and the risk of stroke in clinical practice.
METHODS: From the PHARMO Record Linkage System com-
prising, among others, linked drug-dispensing and hospital
records of >2 million inhabitants in The Netherlands, new users
of AHT were identiﬁed in the period 1993–2002. Persistence
with AHT was determined by summing the number of days of
continuous treatment (gaps between dispensings of <60 days).
Patients were classiﬁed as persistent if they remained on AHT
for at least two years. The outcome of interest was the ﬁrst hos-
pital admission for stroke occurring two or more years after 
initiation of AHT therapy. Patients were classiﬁed as high, inter-
mediate or low cardiovascular risk based on other cardiovascu-
lar drug use and hospitalizations during the ﬁrst two years of
follow-up. RESULTS: The study included 98,485 patients of
whom 16% were at high cardiovascular risk. About 50% (n =
48,548) of all patients were persistent with AHT for two years,
and 2.1% (n = 2093) were hospitalized for stroke in the period
of two or more years after initiation of AHT therapy. Multi-
variate analyses showed that non-persistent users of AHT had a
16%–19% increased risk for stroke compared to persistent users
(Low/intermediate risk group RRadj = 1.19; 95% CI: 1.07–1.32;
high risk group RRadj = 1.16; 95% CI: 0.97–1.39). CONCLU-
SION: In clinical practice antihypertensive drug treatment is used
over too short a time interval to have maximum beneﬁt from
preventing stroke.
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NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS
INCREASES RISK OF HOSPITALIZATIONS FOR ACUTE
MYOCARDIAL INFARCTION BY 10% IN PATIENTS WITH LOW
OR INTERMEDIATE CARDIOVASCULAR RISK
Breekveldt-Postma NS1, Siiskonen SJ1, Penning-van Beest FJA1,
Erkens JA1,Vincze G2, Falvey H2, Herings RMC1
1PHARMO Institute, Utrecht,The Netherlands, 2Novartis Pharma AG,
Basel, Switzerland
OBJECTIVES: Low persistence with antihypertensive drug treat-
ment (AHT) may limit patient’s beneﬁts in terms of a reduction
of cardiovascular and cerebrovascular disease. This study in-
vestigated the relationship between persistence with antihy-
pertensive drugs and the risk of acute myocardial infarction
(AMI) in clinical practice. METHODS: From the PHARMO
record linkage system comprising, among others, linked drug-
dispensing and hospital records of >2 million inhabitants in The
Netherlands, new users of AHT were identiﬁed in the period
1993–2002. Persistence with AHT was determined by summing
the number of days of continuous treatment (gaps between dis-
pensings <60 days). Persistent patients remained on AHT for two
years. The outcome of interest was the ﬁrst hospital admission
for AMI occurring two or more years after initiation of AHT
therapy. Patients were classiﬁed as high, intermediate or low car-
diovascular risk based on other cardiovascular drug use and hos-
pitalizations during the ﬁrst two years of follow-up. RESULTS:
The study included 98,485 patients of whom 16% were at high
cardiovascular risk. About 50% of all patients were persistent
with AHT for two years and 1.5% was hospitalized for AMI in
the period of two or more years after initiation of AHT. Multi-
variate analyses showed that non-persistent use of AHT
increased the risk for AMI in the low/intermediate risk group
(RRadj = 1.12; 95% CI: 0.99–1.28), but not in the high risk
group (RRadj = 0.90; 95% CI: 0.73–1.10). CONCLUSION: In
clinical practice antihypertensive drug treatment is used over too
short a time interval to have maximum beneﬁt for preventing
AMI in patients with low or intermediate cardiovascular risk.
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RELATIONSHIPS BETWEEN VENOUS THROMBOEMBOLIC
(VTE) PROPHYLACTIC TREATMENTS AND VTE
COMPLICATIONS OR THROMBOCYTOPENIA AND AMONG
VETERANS RECEIVING TOTAL HIP REPLACEMENTS
Raisch DW, Campbell HM,Taylor Z
Department of Veterans Affairs Cooperative Studies Program,
Albuquerque, NM, USA
OBJECTIVES: To compare rates of venous thromboembolic
(VTE) complications and thrombocytopenia by VTE prophylac-
tic treatments, among Department of Veterans Affairs (VA)
patients receiving total hip replacement(THR). METHODS:
From the VA national databases, we identiﬁed all THR patients
between March 2003 and March 2004. Using inpatient and out-
patient data; we collected demographics, diagnoses, health care
utilization, and VTE prophylactic strategies for each patient. We
followed patients for 1 year post-surgery, applying diagnostic
codes to identify VTE complications (deep vein thrombosis
(DVT)), pulmonary embolism (PE), post-thrombotic syndrome
(PTS)), and thrombocytopenia. Using logistic regression; con-
trolling for age, gender, obesity, congestive heart failure, and
cancer; we compared VTE complications and thrombocytopenia
by VTE prophylaxis (reference = enoxaparin alone). RESULTS:
We found 1722 THRs with VTE prophylaxis: enoxaparin = 1005
(58.4%), warfarin = 345 (20.0%), dalteparin = 205 (11.9%), and
the combination of enoxaparin with warfarin (enox/warf) = 167
(9.7%). Respectively, patients experiencing VTE complications
(chi square p < 0.001) were: 26 (2.6%), 22 (6.4%), 5 (2.4%),
and 34 (20.4%) or suffering thrombocytopenia (chi square p =
0.177) were: 6 (0.5%), 3 (0.9%), 1 (0.5%), and 4 (2.4%). Logis-
tic regression revealed signiﬁcantly greater (p < 0.001) VTE com-
plications (odds ratio, 95% conﬁdence intervals) with enox/warf
(9.9, 5.6–17.2) or warfarin alone (2.6, 1.5–4.7) versus enoxa-
parin alone. Signiﬁcant covariates were age (p = 0.016) and cancer
diagnosis (p = 0.018). Treatment with enox/warf was associated
with signiﬁcantly (p < 0.001) more PEs, 4.8% versus 0.5% (10.6,
3.7–33.6). Treatment with enox/warf or warfarin alone was asso-
ciated with more (p < 0.001) DVTs, 17.4% versus 2.2% (9.4,
5.2–17.1) and 5.2% versus 2.2% (2.5, 1.3–4.8). There were no
cases of PTS. Logistic regression results for thrombocytopenia
were not signiﬁcant (p = 0.174). CONCLUSION: Warfarin and
enox/warf were signiﬁcantly less effective VTE prophylactic
strategies following THR than dalteparin or enoxaparin. Poten-
tial limitations include the non-controlled, observational design,
inclusion of primarily male VA patients, and constraints inherent
in national VA data.
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OBJECTIVES: Statins are the most widely used drugs for the
management of hyperlipidemia and are generally well tolerated;
however, statin-associated myopathy is a major clinical concern.
The risk of myopathy further increases when statins are used
concurrently with potentially interacting medications (PIMs).
The purpose of this study was to evaluate the risk and risk
factors of myopathy in patients using statins with PIMs com-
pared to those patients using statins without PIMs. METHODS:
The study was a retrospective cohort analysis using the Texas
Medicaid database. The study population included patients who
were new statin users between the ages of 21 and 64 years and
were eligible for Texas Medicaid beneﬁts between September 1,
1998 and August 31, 2003. The main outcome measures were
incidence rates of myopathy per 100 person-months of treatment
and odds of developing myopathy. RESULTS: In 8822 eligible
patients, 113 cases of myopathy occurred during an average
follow-up of 3.9 months. The overall incidence of myopathy in
the study population was 0.32 per 100 person-months. Patients
using statins with PIMs had a 2.7-fold (95% CI: 1.830–4.030)
greater risk of developing myopathy than patients using statins
without PIMs. In addition, increasing number of comorbidities
was associated with 1.3 times (95% CI: 1.159–1.637) greater
risk of myopathy. Also, the risk of myopathy decreased (OR:
0.997; 95% CI: 0.995–0.999) with increasing statin use. CON-
CLUSION: The risk of myopathy was higher for patients using
statins and PIMs as compared to patients using statins without
PIMs. Health care professionals should monitor patients closely
when they use statins and PIMs concurrently, especially those
with multiple comorbidities.
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ISOLATED SYSTOLIC HYPERTENSION IN A COHORT OF
INNER CITY MINORITY PATIENTS
Shaya FT, Gu A
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: To study the prevalence and identify predictors
of isolated systolic hypertension in a cohort of inner city hyper-
tensive patients, predominantly African American. METHODS:
The study cohort is composed of 327 hypertensive patients,
enrolled in the NHLBI Baltimore Partnership Programs to
Reduce CVD Disparities project. We deﬁned isolated systolic
hypertension as systolic blood pressure (SBP) ≥ 150 mmHg and
diastolic blood pressure (DBP) lower than 90 mmHg. Potential
predictors included in the logistic regression model are family
history of cardiovascular diseases, self-perceived good health
status, older age (65+) and being African American. RESULTS:
About 10% (32 out of the 327) of hypertensive patients had iso-
lated systolic hypertension at baseline. Patients over 65 (p < 0.01)
and those who perceived their health status to be less than
“good” (p < 0.05) were more likely to have isolated systolic
hypertension. CONCLUSION: In this patient sample, the preva-
lence of isolated systolic hypertension is approximately 10%.
Self perceived health status and senility are both signiﬁcant pre-
dictors of having isolated systolic hypertension. These results
may inform the management of hypertension to help improve
blood pressure control rates.
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CLINICAL OUTCOME OF HYPERTENSION MANAGEMENT:A
FIVE YEAR OBSERVATIONAL STUDY
Lee VWY, Chan TH, Ko TT, Lee KK,Tomlinson B
The Chinese University of Hong Kong, Hong Kong, China
OBJECTIVES: The current study was: 1) to investigate the
prevalence and extent to which the systolic blood pressure (SBP)
and diastolic blood pressure (DBP) of patients with hypertension
deviated from the pre-deﬁned treatment goals, and 2) to observe
the association between the extent of deviation from target and
the short-term prognosis of the patient. METHODS: Adult
patients who were seen at the Prince of Wales Hospital outpa-
tient clinic with the baseline period between Janaury 1, 2000 to
December 31, 2000 were recruited. Retrospective chart review
was conducted for a period of 5 years. Recruited Patients had a
primary diagnosis of stage I or II hypertension according to 
the JNC-7 guidelines; were on mono- or combination anti-
hypertensive therapy; had never attended any nurse counseling
sections or pharmacist concordance clinics. The primary out-
come measurement was the prevalence, duration, and extent of
SBP and DBP deviation from the treatment goals at baseline and
at each study time point. The secondary outcome measurement
was the number of incidences of cardiovascular diseases (fatal or
non-fatal myocardial infarction, congestive heart failure, angina
pectoris) and cerebrovascular events (stroke), the number of
coronary procedures performed, and the mortality from all car-
diovascular or cerebrovascular causes, and the total mortality at
each study time point. RESULTS: A total of 1367 patients were
identiﬁed. To date, 157 patients’ charts were reviewed (age
range: 21–78 years old; mean age: 52.79 years old). Over 30%
of patients had a positive family history of coronary heart dis-
eases. The SBP and DBP were not control over 40% of the study
time period in 55.4% and 35% patients respectively. The total
event rate for the 5-year period was observed in 48 patients
(30.6%). CONCLUSION: Overall antihypertensive manage-
ment was encouraging but there is room for improvement.
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THE EFFECTS OF SEASONAL VARIATIONS AND WEATHER
CONDITIONS ON THE OCCURRENCE OF HEART ATTACKS IN
HUNGARY BETWEEN 2000–2004
Kriszbacher I1, Boncz I2, Oláh A1, Bódis J1
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund
Administration, Budapest, Hungary
OBJECTIVES: The spatial and temporal changes of weather
factors depend on geographical location, seasons and the time of
the day. The onset of acute myocardial infarct (AMI) shows
certain circadian rhythms and seasonal variation, which are
inﬂuenced by sex, age and the changes of the weather as well.
Our study examines the relationships of meteorological factors
and the incidence of AMI. METHODS: A retrospective analysis
of patients diagnosed with AMI between 2000 and 2004 in
Hungary (n = 81,956 patients) was carried out. Data were
derived from the National Health Insurance Fund Administra-
tion (OEP) containing routinely collected ﬁnancial data. When-
ever the same patient occurred in the database several times, it
has been considered as a separate case. Weather related data
were provided by the National Meteorology Service (OMSZ).
RESULTS: A peak period of the occurrence of AMI was found
during spring, while minimum number of events was recorded
during summer. Signiﬁcant difference was observed between the
number of events each season (F = 34.741; p < 0.001; N =
81,956). A medium level negative correlation was found between
the monthly average temperature and the occurrence of AMI (r
= −0.404) during the period examined. A positive correlation
was shown between front movements and the number of events
per season (r = 0.053). Average barometric pressure changes, the
number of front movements and the number of AMI events also
showed a nearly similar seasonal deviation. CONCLUSION:
Our ﬁndings show that certain meteorological factors may be
related to the onset of AMI, however other factors also play an
important role.
